CN105229150A - 用于治疗癌症干细胞的反义寡核苷酸 - Google Patents

用于治疗癌症干细胞的反义寡核苷酸 Download PDF

Info

Publication number
CN105229150A
CN105229150A CN201480026262.3A CN201480026262A CN105229150A CN 105229150 A CN105229150 A CN 105229150A CN 201480026262 A CN201480026262 A CN 201480026262A CN 105229150 A CN105229150 A CN 105229150A
Authority
CN
China
Prior art keywords
cancer
oligonucleotide
individual
administered
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026262.3A
Other languages
English (en)
Chinese (zh)
Inventor
L·O·布尔齐奥埃里兹
V·A·布尔齐奥梅嫩德斯
J·E·维勒加斯奥拉瓦里亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andean Global Ltd By Share Ltd
Original Assignee
Andes Biotechnologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andes Biotechnologies SA filed Critical Andes Biotechnologies SA
Priority to CN202210729571.3A priority Critical patent/CN115518073A/zh
Publication of CN105229150A publication Critical patent/CN105229150A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480026262.3A 2013-03-14 2014-03-14 用于治疗癌症干细胞的反义寡核苷酸 Pending CN105229150A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210729571.3A CN115518073A (zh) 2013-03-14 2014-03-14 用于治疗癌症干细胞的反义寡核苷酸

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361785269P 2013-03-14 2013-03-14
US61/785,269 2013-03-14
US201361790072P 2013-03-15 2013-03-15
US61/790,072 2013-03-15
US201461937438P 2014-02-07 2014-02-07
US61/937,438 2014-02-07
PCT/US2014/029606 WO2014153209A1 (en) 2013-03-14 2014-03-14 Antisense oligonucletotides for treatment of cancer stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210729571.3A Division CN115518073A (zh) 2013-03-14 2014-03-14 用于治疗癌症干细胞的反义寡核苷酸

Publications (1)

Publication Number Publication Date
CN105229150A true CN105229150A (zh) 2016-01-06

Family

ID=51581450

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480026262.3A Pending CN105229150A (zh) 2013-03-14 2014-03-14 用于治疗癌症干细胞的反义寡核苷酸
CN202210729571.3A Pending CN115518073A (zh) 2013-03-14 2014-03-14 用于治疗癌症干细胞的反义寡核苷酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210729571.3A Pending CN115518073A (zh) 2013-03-14 2014-03-14 用于治疗癌症干细胞的反义寡核苷酸

Country Status (13)

Country Link
US (3) US9862944B2 (https=)
EP (1) EP2970970B1 (https=)
JP (1) JP6313419B2 (https=)
CN (2) CN105229150A (https=)
BR (1) BR112015022308A8 (https=)
CA (1) CA2906198C (https=)
CL (1) CL2015002612A1 (https=)
DK (1) DK2970970T3 (https=)
ES (1) ES2708650T3 (https=)
HU (1) HUE042738T2 (https=)
MX (1) MX359337B (https=)
PL (1) PL2970970T3 (https=)
WO (1) WO2014153209A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113893261A (zh) * 2021-06-22 2022-01-07 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circITGB6-ASO与铂类化疗药物联合使用在制备治疗卵巢癌的药物中的应用
EP3954764A4 (en) * 2019-04-11 2022-07-13 Genex Health Co.,Ltd METHODS FOR CULTIVATION OF PRIMARY CELLS OF STOMACH AND GALLBLADDER AND BILE DUCT CANCER AND SUPPORTING REAGENTS

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970970T3 (en) 2013-03-14 2019-02-11 Andes Biotechnologies Global Inc Antisense oligonucleotides for the treatment of cancer stem cells
EP2970364B1 (en) 2013-03-14 2019-04-24 Andes Biotechnologies Global, Inc. Methods for detecting and treating multiple myeloma
KR102145176B1 (ko) * 2017-11-27 2020-08-18 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001030A2 (en) * 2003-05-21 2005-01-06 Bios Chile I.G.S.A. Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein
US20100292099A1 (en) * 2007-08-23 2010-11-18 Keren Pharmaceutical, Inc. Targeting of rna with external guide sequences

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
ES2083593T3 (es) 1990-08-03 1996-04-16 Sterling Winthrop Inc Compuestos y metodos para inhibir la expresion de genes.
CA2092002A1 (en) 1990-09-20 1992-03-21 Mark Matteucci Modified internucleoside linkages
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
CA2159629A1 (en) 1993-03-31 1994-10-13 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
AU2006305141B2 (en) 2005-10-20 2010-07-08 Tokuyama Corporation Method for removing mixed air in coating liquid and apparatus therefor
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
EP2023940B1 (en) 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
CA2706293A1 (en) 2007-11-20 2009-05-28 Hopitaux Universitaires De Geneve Methods for identifying, purifying and enriching immature or stem cancer-initiating cells from tumors and use thereof
DK2470656T3 (da) * 2009-08-27 2015-06-22 Idera Pharmaceuticals Inc Sammensætning til hæmning af genekspression og anvendelser heraf
DK2970970T3 (en) 2013-03-14 2019-02-11 Andes Biotechnologies Global Inc Antisense oligonucleotides for the treatment of cancer stem cells
EP2970364B1 (en) 2013-03-14 2019-04-24 Andes Biotechnologies Global, Inc. Methods for detecting and treating multiple myeloma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001030A2 (en) * 2003-05-21 2005-01-06 Bios Chile I.G.S.A. Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein
US20060241033A1 (en) * 2003-05-21 2006-10-26 Luis Burzio Markers for pre-cancer and cancer calls and the method to interfere with cell proliferation therein
US20100292099A1 (en) * 2007-08-23 2010-11-18 Keren Pharmaceutical, Inc. Targeting of rna with external guide sequences

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3954764A4 (en) * 2019-04-11 2022-07-13 Genex Health Co.,Ltd METHODS FOR CULTIVATION OF PRIMARY CELLS OF STOMACH AND GALLBLADDER AND BILE DUCT CANCER AND SUPPORTING REAGENTS
CN113893261A (zh) * 2021-06-22 2022-01-07 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circITGB6-ASO与铂类化疗药物联合使用在制备治疗卵巢癌的药物中的应用
CN113893261B (zh) * 2021-06-22 2023-01-13 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circITGB6-ASO与铂类化疗药物联合使用在制备治疗卵巢癌的药物中的应用

Also Published As

Publication number Publication date
EP2970970A1 (en) 2016-01-20
DK2970970T3 (en) 2019-02-11
US11319535B2 (en) 2022-05-03
HK1220482A1 (en) 2017-05-05
US20180171335A1 (en) 2018-06-21
CA2906198C (en) 2022-11-29
PL2970970T3 (pl) 2019-06-28
US10457943B2 (en) 2019-10-29
US9862944B2 (en) 2018-01-09
BR112015022308A8 (pt) 2018-01-23
HUE042738T2 (hu) 2019-07-29
MX2015012063A (es) 2016-04-06
WO2014153209A8 (en) 2015-02-26
BR112015022308A2 (pt) 2017-10-10
CA2906198A1 (en) 2014-09-25
MX359337B (es) 2018-07-09
WO2014153209A1 (en) 2014-09-25
EP2970970B1 (en) 2018-12-12
US20160138015A1 (en) 2016-05-19
US20200239885A1 (en) 2020-07-30
JP6313419B2 (ja) 2018-04-18
CN115518073A (zh) 2022-12-27
JP2016519084A (ja) 2016-06-30
CL2015002612A1 (es) 2016-08-26
EP2970970A4 (en) 2016-10-19
ES2708650T3 (es) 2019-04-10

Similar Documents

Publication Publication Date Title
US11319535B2 (en) Antisense oligonucleotides for treatment of cancer stem cells
US20230242913A1 (en) Sting-dependent activators for treatment of disease
CN107249644A (zh) 针对转铁蛋白受体(TfR)的RNA适体
US20200299696A1 (en) Aptamer compositions and the use thereof
AU2010202302A1 (en) Antisense Oligonucleotides directed to Ribonucleotide reductase R2 and uses thereof in the treatment of cancer
AU2011301712B2 (en) Method for reducing the number of certain circulating leukocytes in a human subject
US20230040280A1 (en) Antisense oligonucleotides for treatment of cancer stem cells
JP2007520474A (ja) リボヌクレオチドレダクターゼｒ２に向けられたアンチセンスオリゴヌクレオチドおよび癌の処置のための併用療法におけるこの使用
US9518300B2 (en) Composition and method for treating a hematological malignancy
EP2970364B1 (en) Methods for detecting and treating multiple myeloma
WO2023212572A2 (en) Long non-coding rna 122 (lnc122) for treating cancer
HK1220482B (en) Antisense oligonucleotides for treatment of cancer stem cells
CN107106697A (zh) Pdgfr rna适体
AU2016349954B2 (en) Mobilizing leukemia cells
US20250066784A1 (en) Therapeutic oligonucleotides
US20170183650A1 (en) Pharmaceutical compositions comprising rna and use for treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Santiago

Applicant after: Andean biotechnology Co.

Address before: Santiago

Applicant before: ANDES BIOTECHNOLOGIES S.A.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180116

Address after: California, USA

Applicant after: Andean global Limited by Share Ltd.

Address before: Santiago

Applicant before: Andean biotechnology Co.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160106